| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $54,436,409 ) (Continued on the next page) |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL163857 | Premature aging disorders, metabolites, and atherosclerosis | 001 | 4 | NIH | 3/27/2026 | $21,165 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DK132019 | Angiotensin Signaling Underlies Myeloid and Sensory Disruption in Diabetes | 000 | 3 | NIH | 4/17/2026 | $398,433 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 001 | 4 | NIH | 4/16/2026 | $49,400 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA276235 | Cis-aconitate decarboxylase (ACOD1) in PMN-MDSC and prostate cancer progression | 001 | 4 | NIH | 4/16/2026 | $37,057 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31DE035777 | The Development of an early detection tool for oral-dental radiation induced injury | 002 | 1 | NIH | 4/16/2026 | $576 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA275990 | Novel Approaches Targeting B7-H3 in Castration-resistant Prostate Cancer | 001 | 4 | NIH | 4/16/2026 | $58,806 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299972 | Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions | 001 | 2 | NIH | 4/16/2026 | $67,755 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA260661 | Metabolic basis of ARID1A-mutated ovarian cancer | 001 | 5 | NIH | 4/16/2026 | $49,843 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM156417 | Computational and experimental approaches for decoding the function and regulation of unconventional RNA translation | 001 | 2 | NIH | 3/11/2026 | $44,962 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R00CA296940 | Adverse gut microbiome promotes resistance immune checkpoint inhibitors via chronic inflammation | 000 | 2 | NIH | 4/17/2026 | $248,658 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279749 | Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events | 001 | 3 | NIH | 4/16/2026 | $63,575 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269140 | Targeting the LIFR-LCN2 pathway to improve liver cancer therapy | 001 | 4 | NIH | 4/16/2026 | $48,014 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA255960 | Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients | 001 | 5 | NIH | 4/16/2026 | $47,574 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA288827 | Deciphering the Critical Determinants of Enteric and Tumor Niche Colonization by Microbes in Colorectal Cancer | 001 | 2 | NIH | 4/16/2026 | $68,191 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA270010 | Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer | 001 | 4 | NIH | 4/16/2026 | $47,386 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K22CA279077 | Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics | 001 | 3 | NIH | 4/16/2026 | $19,224 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R00CA287069 | A Chemoproteomic Approach to Identify Molecular Glues for Targeted Cancer Therapy | 001 | 3 | NIH | 4/16/2026 | $24,900 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278971 | Esophageal Squamous Cell Cancer Initiation and Immune Landscape Remodeling | 001 | 3 | NIH | 4/16/2026 | $52,060 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278967 | CRACD-controlled cell plasticity and small cell lung cancer | 001 | 3 | NIH | 4/16/2026 | $60,894 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | T32CA009599 | Training of Academic Surgical Oncologists | 000 | 38 | NIH | 5/1/2026 | $596,268 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R25CA181004 | MD Anderson Summer Program in Cancer Research (SPCR) | 000 | 12 | NIH | 5/5/2026 | $242,094 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA307194 | Proline tRNA biogenesis as oncogenic drivers and therapeutic target in T cell acute lymphoblastic leukemia | 000 | 1 | NIH | 4/9/2026 | $473,372 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA307595 | Drug-loaded degradable biopolymeric scaffolds for augmenting preoperative liver growth | 000 | 1 | NIH | 3/30/2026 | $680,129 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K08CA296776 | Harnessing ecDNA Detection in Antigen-Presenting Cells for Anti-Tumor Immunity | 000 | 2 | NIH | 5/7/2026 | $139,247 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DA041711 | Signaling Mechanisms of Opioid-Induced Hyperalgesia and Tolerance | 000 | 9 | NIH | 4/28/2026 | $447,865 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS132398 | Mechanisms of Epigenetic Plasticity in Neuropathic Pain | 000 | 4 | NIH | 3/30/2026 | $487,743 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA261952 | Role of the pro-inflammatory omental microenvironment in ovarian cancer progression | 000 | 5 | NIH | 5/5/2026 | $430,976 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS146081 | Targeting RNF2 to Synergize with Oncolytic Immunovirotherapy to Induce Anti-Cancer Immunity in Medulloblastoma | 000 | 1 | NIH | 5/1/2026 | $421,361 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U54CA280804 | Center for Transformative Community-Driven Research to Prevent Obesity-related Cancer | 002 | 4 | NIH | 5/4/2026 | $1,947,476 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | T32CA196561 | Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology | 000 | 10 | NIH | 5/1/2026 | $1 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299261 | Detection and elimination of drug tolerant persister cells in small cell lung cancer | 000 | 2 | NIH | 3/31/2026 | $424,836 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279119 | Alpha particles combined with ATR inhibition to activate the immune system: mechanisms and pre-clinical translation | 000 | 4 | NIH | 5/7/2026 | $520,199 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | UG1CA233329 | UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAPS) UG1 | 000 | 7 | NIH | 5/7/2026 | $926,653 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA271540 | Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLC | 001 | 4 | NIH | 4/7/2026 | $658,606 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HD112473 | Role of PRMT7 in Genomic Imprinting | 000 | 4 | NIH | 5/7/2026 | $348,300 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DK142664 | Regulation of Mitochondrial Respiration in Diabetic Kidney Disease | 000 | 2 | NIH | 4/7/2026 | $565,025 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA312836 | Deciphering the Role of Tumor Suppressor Gene Deficiencies in Modulating PDAC Response to Oncogenic KRAS Inhibition and Immunotherapy | 000 | 1 | NIH | 5/7/2026 | $141,195 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299653 | Functional characterization of the lineage plasticity landscape of cholangiocarcinoma | 000 | 1 | NIH | 4/7/2026 | $510,671 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM149226 | Regulation of Overall Cell Numbers During Epithelial Tissue Homeostasis and Pathogenesis | 000 | 4 | NIH | 4/2/2026 | $421,200 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269495 | Mechanisms of fasting-induced radioprotection of small intestinal epithelial cells | 000 | 4 | NIH | 5/7/2026 | $661,519 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA293361 | Modulation of the tumor microenvironment by Fusobacterium nucleatum and co-infecting microbes in colorectal cancer | 000 | 1 | NIH | 4/2/2026 | $660,541 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | P40OD024628 | Specific Pathogen Free 18 Baboon Research Resource (SPF18BRR) | 001 | 9 | NIH | 4/28/2026 | $1,274,599 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31HD113306 | Molecular and Cellular Regulation of Uterine Morphogenesis | 001 | 3 | NIH | 4/1/2026 | $576 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL178867 | Dissect the consequences of telomere stress on hematopoietic stem cells | 000 | 1 | NIH | 4/24/2026 | $819,998 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279194 | Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC. | 000 | 4 | NIH | 4/27/2026 | $370,575 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R35GM134744 | Epigenetic regulations of DNA and histone methylation and deMethylation: Structures and Mechanisms | 000 | 7 | NIH | 4/2/2026 | $660,050 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA047296 | A Pathway of Tumor Suppression | 000 | 38 | NIH | 3/26/2026 | $466,560 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 001 | 6 | NIH | 4/16/2026 | $40,867 |
| | 2026 | 2026 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | T32CA261856 | Image Guided Cancer Therapy Training Program | 000 | 5 | NIH | 4/17/2026 | $93,165 |
|
